FibroGen receives Nasdaq delisting notice over bid price below $1.00

KYNTRA BIO, INC.

Nasdaq notified FibroGen on Sept 12 that its stock closed below $1.00 for 30 consecutive days, triggering potential delisting.
FibroGen has 180 days, until March 11, 2025, to regain compliance by achieving a closing bid of at least $1.00 for ten consecutive business days.
If not compliant by March 11, FibroGen may seek an additional 180-day period if it meets other listing requirements and intends to cure, e.g., via reverse stock split.
FibroGen currently meets all other Nasdaq continued listing standards except the bid price requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.